ABGSC acted as sole bookrunner to Zelluna ASA in connection with its NOK 55m private placement of new shares

On 18 June 2026, Zelluna ASA (“Zelluna” or the “Company”) announced a private placement raising gross proceeds of NOK 55 million through the issuance of new shares at a subscription price of NOK 18.5 per share. The subscription price represented a ~10% discount to Zelluna’s closing share price on the day of the launch of the transaction.

Zelluna is a clinical-stage cell therapy company developing next-generation cancer treatments by combining two clinically validated cell therapy approaches: T-cell receptors (TCRs) and natural killer (NK) cells. The net proceeds from the Private Placement will primarily be used to support continued enrolment and treatment of additional patients in the Company’s Phase 1 study of ZI-MA4-1, continued development of the TCR-NK platform, and for general corporate purposes.

The proceeds are expected to provide Zelluna with increased financial flexibility and operational runway as it begins generating initial clinical data, enabling the Company to pursue strategic M&A and partnering opportunities as the lead programme advances. With initial clinical data expected to emerge from mid-2026, Zelluna is entering an important phase in its development. By strengthening its financial position ahead of these data readouts, the Company aims to maintain strategic flexibility as the lead programme advances and initial human data become available.

ABG Sundal Collier is pleased to have advised Zelluna in connection with the private placement as the Sole Bookrunner and would like to thank the Company for the assignment.